Drug Trial Radar · NCT07258407
A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
Last checked: Nov 19, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Jan 30, 2026
Primary completion
Mar 2028
Study completion Mar 2029
Sponsor
- Lead sponsor
- T.O.A.D. Oncology SAIndustry
- Sponsor type
- Industry
- First posted
- Dec 2, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, tolerability, drug levels (pharmacokinetics) and preliminary antitumor activity of TD001, an antibody-drug conjugate (ADC) targeting prostate-specific membrane antigen (PSMA), in men with metastatic PSMA-expressing castration-resistant prostate cancer (CRPC).
Conditions
- Metastatic Castration-Resistant Prostatic Cancer
Interventions
TD001Drug
Intravenous (IV) infusion at protocol-defined doses and schedules until disease progression or other reason to end treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (dose escalation)Time frame: Treatment + follow-up (estimated 9 months)
- Recommended Phase 2 doses (dose escalation)Time frame: Treatment + follow-up (estimated 9 months)
- Safety/tolerability - incidence of AEs, SAEs, abnormal laboratory parameters (dose escalation + expansion)Time frame: Treatment + follow-up (estimated 21 months)
- Safety/tolerability - incidence of TD001 discontinuation or modification due to AEs (dose escalation + expansion)Time frame: Treatment + follow-up (estimated 21 months)
Locations
7 sites in 5 countries. Site status is shown where the registry gives one.
Yale University, Yale Cancer Center
New Haven, Connecticut · Not yet recruiting
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia · Recruiting
Princess Margaret Cancer Centre
Toronto, Ontario, Canada · Recruiting
Institut Bergonié
Bordeaux, France · Recruiting
Hôpital Paris Saint Joseph
Paris, France · Recruiting
Institut Gustave Roussy
Villejuif, France · Recruiting
Vall d'Hebron Institute of Oncology
Barcelona, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.